Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
Publication/Presentation Date
3-1-2024
Abstract
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of the Goldspire™ platform, is a first-in-class autologous immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, with the intent to induce a tumor-specific immune response in patients with ndGBM. Here, we describe the design and rationale of a randomized, double-blind, phase IIb trial evaluating IGV-001 compared with placebo, both followed by standard-of-care treatment in patients with ndGBM. The primary end point is progression-free survival, and key secondary end points include overall survival and safety.
Volume
20
Issue
10
First Page
579
Last Page
591
ISSN
1744-8301
Published In/Presented At
Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., Scott, C., … Boockvar, J. A. (2024). Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients. Future oncology (London, England), 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
38060340
Department(s)
Administration and Leadership
Document Type
Article